DBV Technologies | DBVT - Assets

Stock Price
19.65
Daily Change
-0.19 -0.96%
Monthly
-4.66%
Yearly
77.03%
Q2 Forecast
19.19

DBV Technologies reported $233.72M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amarin USD 645.76M 25.01M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
DBV Technologies USD 233.72M 123.22M Dec/2025
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026